The company reported that net sales rose 28% to $567 million. For the first half of 2021, net sales rose 39% to $1.14 billion.

Diluted earnings per share (EPS) was 52¢ in the second quarter of 2021, while the adjusted EPS was 67¢ against the outlook for a coupon equivalent rate of 62¢ to 64¢. The EPS was up 22% from 55¢ in the second quarter of 2020. For the first half of 2021, the diluted EPS was $1.08, while the adjusted EPS was $1.33, up 49% from 89¢ in the first half of 2020.

Company leaders said the results are driven by performance in the company's non-COVID product groups.

Qiagen launches workflow configurator
Netherlands-based sample and assay technology provider Qiagen announced it has launched a cloud-based workflow tool to help researchers simplify and optimize...

Qiagen and Sysmex form strategic alliance
Qiagen announced it has entered a strategic alliance with partner Sysmex for the development and commercialization of next-generation sequencing products...

Qiagen launches CRISPR products to aid in edited genetic material analysis
Qiagen has rolled out its QIAprep & CRISPR Kit and CRISPR Q-Primer Solutions. The products are intended to support researchers in analyzing edited...

Qiagen posts strong sales, earnings growth in Q1
Strong growth in both COVID-19 and non-COVID-19 product groups propelled Qiagen to a 48% increase in net sales at constant exchange rates in its first...

Qiagen introduces EZ2 Connect platform
Qiagen has announced the upcoming launch of the EZ2 Connect product line, an automated sample-processing platform that aims to benefit biomedical research,...